TREM2 and Alzheimer disease: According to research reports, Chronic M0-differentiation may lead Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which serves as a putative therapeutic target for AD, to increased synthesis in AD-derived cells (Cosma et al., 2023).